Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS -mutant advanced non-small cell lung cancer: the SELECT -1 randomized clinical trial.
dc.contributor.author | Jänne, P | |
dc.contributor.author | van den Heuvel, M | |
dc.contributor.author | Barlesi, F | |
dc.contributor.author | Cobo, M | |
dc.contributor.author | Mazieres, J | |
dc.contributor.author | Crinò, L | |
dc.contributor.author | Orlov, S | |
dc.contributor.author | Blackhall, Fiona H | |
dc.contributor.author | Wolf, J | |
dc.contributor.author | Garrido, P | |
dc.contributor.author | Poltoratskiy, A | |
dc.contributor.author | Mariani, G | |
dc.contributor.author | Ghiorghiu, D | |
dc.contributor.author | Kilgour, E | |
dc.contributor.author | Smith, P | |
dc.contributor.author | Kohlmann, A | |
dc.contributor.author | Carlile, D | |
dc.contributor.author | Lawrence, D | |
dc.contributor.author | Bowen, K | |
dc.contributor.author | Vansteenkiste, J | |
dc.date.accessioned | 2017-06-29T10:15:56Z | |
dc.date.available | 2017-06-29T10:15:56Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS -mutant advanced non-small cell lung cancer: the SELECT -1 randomized clinical trial. 2017, 317 (18):1844-1853 JAMA | en |
dc.identifier.issn | 1538-3598 | |
dc.identifier.pmid | 28492898 | |
dc.identifier.doi | 10.1001/jama.2017.3438 | |
dc.identifier.uri | http://hdl.handle.net/10541/620404 | |
dc.description.abstract | There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to JAMA | en |
dc.title | Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS -mutant advanced non-small cell lung cancer: the SELECT -1 randomized clinical trial. | en |
dc.type | Article | en |
dc.contributor.department | Lowe Center for Thoracic Oncology and the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts | en |
dc.identifier.journal | JAMA | en |
html.description.abstract | There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer. |